Skip to content

Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial

Effects of vaginal administration of conjugated estrogens tablet on sexual function in postmenopausal women with sexual dysfunction: a double-blind, randomized, placebo-controlled trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20180219001
Enrollment
60
Registered
2018-02-19
Start date
2018-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sexual function in postmenopausal women conjugated estrogens tablet vaginal administration sexual function postmenopausal women sexual dysfunction Vaginal pH Vaginal atrophy symptoms Vaginal maturation index Number of lactobacilli&#44

Interventions

vaginal administration of oral conjugated estrogens tablet (Estromon 0.625 mg) 1 tablet once daily for 3 weeks then 1 tablet twice weekly for 9 weeks,vaginal administration of oral conjugated estrogen
Experimental Drug,Placebo Comparator Drug
vaginal administration of conjugated estrogens tablet,vaginal administration of conjugated estrogens tablet placebo

Sponsors

Ratchadapiseksompot Endowment Fund
Lead Sponsor
Faculty of medicine&#44
Collaborator
Chulalongkorn University
Collaborator

Eligibility

Sex/Gender
Female
Age
45 Years to 70 Years

Inclusion criteria

Inclusion criteria: Being amenorrhea for at least 1 year (according to diagnostic definition of menopause by WHO) Consent was given Vaginal pH >5 Atleast on vaginal atrophic symptoms in moderate intensity TFSFI score not over 26.5 Well communicable in Thai History of engagement in sexual intercourse at least 2 times a month

Exclusion criteria

Exclusion criteria: Pathologic cause of menopause : primary ovarian insufficiency, underwent oophorectomy, radiation/chemotherapy induced menopause History of receiving hormone or other therapy affecting vaginal mucosa History of abnormal vaginal discharge or bleeding not yet evaluated nor treated History of vaginal or cervical surgery within 3 months prior to enrollment Personal or family history of estrogen related malignancy Having contraindication for hormonal use History of sex steroid hormone / steroid use within 2 months prior to enrollment History of psychiatric condition Having active sexual partner with history of sexual dysfunction

Design outcomes

Primary

MeasureTime frame
sexual function in postmenopausal women at 12 weeks after starting of the intervention FSFI score

Secondary

MeasureTime frame
Vaginal atrophy symptoms (The most bothersome symptom) at 12 weeks after starting of the intervention Vaginal atrophy symptoms (The most bothersome symptom),Vaginal pH at 12 weeks after starting of the intervention pH paper,The number of lactobacilli at 12 weeks after starting of the intervention Gram staining and count under light microscope with magnification,vaginal maturation index at 12 weeks after starting of the intervention Staining and count under light microscope with magnification,Normal Flora Index at 12 weeks after starting of the intervention Gram staining and count under light microscope with magnification

Countries

Thailand

Contacts

Public ContactThanapob Bumphenkiatikul

Unaffiliated

tBumphenkiatikul@gmail.com+66865709490

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026